Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Single-Arm, Single-Center Study of BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in Relapsed or Refractory Multiple Myeloma.

Next Previous
Trial Profile

A Prospective Single-Arm, Single-Center Study of BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in Relapsed or Refractory Multiple Myeloma.

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gamgertamig (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CM336-001

Most Recent Events

  • 12 Feb 2026 Status changed from planning to not yet recruiting.
  • 16 Jan 2025 New trial record
  • 10 Jan 2025 According to Ouro Medicines media release, Ouro holds exclusive rights outside of Greater China and intends to start its first Phase 1 study in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top